^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II trial to evaluate the efficacy and safety of vemetinib (ifaxa) plus anlotinib hydrochloride (forcovil) in patients with locally advanced or metastatic non-small cell lung cancer who had disease progression after osimertinib (teresha) treatment
Excerpt:
...Patients with EGFR or T790M mutation were confirmed by different detection methods. ...
Trial ID:
Source:
Title:
An exploratory clinical study on the the correlation of efficacy and adverse reactions of anlotinib combined with osimertinib in the treatment of EGFR-positive advanced non-small cell lung cancer between blood concentration and population pharmacokinetics
Excerpt:
...Can provide high-throughput oncogene assay reports, including EGFR mutation sites and mutation abundance, or can provide tumor tissue samples for throughput oncogene assay; 7. ...
Trial ID:
More C2 evidence
Source:
Title:
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
Excerpt:
...The tumour harbours one of the most common EGFR mutations known to be associated with EGFR-TKI sensitivity (exon 19 deletion; L858R) either alone or in combination with other EGFR mutations as confirmed by a local test....
Source:
Title:
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
Excerpt:
...Presence of EGFR activating mutations and previously disease progression to Osimertinib (previously treated with 1st / 2nd generation EGFR-TKI or not)； 4....
Source:
Title:
Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M
Excerpt:
...Non-small cell lung cancer (NSCLC) with an activating EGFR mutation (exon 19 deletion, L858R point mutation, or any other mutation known to be associated with EGFR TKI sensitivity); presence of an activating EGFR mutation may be documented in tumor tissue or by plasma testing....
Source:
Title:
Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment
Excerpt:
...Patients should be confirmed acquired EGFR T790M mutation and received osimertinib as the second line treatment, and they should have the following: (1) benefit from treatment with osimertinib initially ;(2) gradual progression on osimertinib treatment as defined by minor increment of tumor burden (≥10% but ...
Trial ID:
Source:
Title:
Osimertinib plus Anlotinib as first-line treatment for coexisting EGFR mutation advanced NSCLC: a single-arm, open-label, phase II study
Excerpt:
...NSCLC Patients presenting with an EGFR activating mutation (19del or 21 L858R or T790M) according to any validated method and containing one or more of TP53, PIK3CA, KRAS, MYC, RB1 by NGS sequencing; 6. ...
Trial ID:
Less C2 evidence
Source:
Title:
Phase Ib/IIa study evaluating the safety and clinical activity of osimeritinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients (AUTOMAN).
Published date:
05/26/2022
Excerpt:
In this phase Ib/IIa, open-label study, treatment-naïve patients with an activating EGFR mutation, advanced or metastatic lung adenocarcinoma were eligible....Among 23 response evaluable patients, the overall ORR was 65.2% (95%CI 42.7,83.6), DCR was 95.7% (95%CI 78.0,99.9) and median depth of response was -40.7% (range, -70.6 to 49.7)....Osimertinib in combination with anlotinib as first-line treatment for naïve EGFRm advanced NSCLC patients showed encouraging antitumor activity with manageable safety profile.
Trial ID:
Source:
Title:
1238P-AUTOMAN: A phase Ib/IIa study of osimertinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients
Published date:
09/13/2021
Excerpt:
The ORR was 87.5% (95% CI 52.9, 97.8), DCR was 100% (95% CI 67.6, 100.0) and median depth of response was 35.0% (range 26%-71%)….Osimertinib in combination with Anlotinib is well tolerated and has demonstrated encouraging antitumor activity in treatment naïve EGFRm advanced NSCLC patients.
Trial ID:
